MARKET

ATHX

ATHX

Athersys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.550
+0.010
+0.65%
After Hours: 1.550 0 0.00% 17:58 05/11 EDT
OPEN
1.440
PREV CLOSE
1.540
HIGH
1.580
LOW
1.400
VOLUME
3.07M
TURNOVER
--
52 WEEK HIGH
3.390
52 WEEK LOW
1.400
MARKET CAP
344.23M
P/E (TTM)
-3.7046
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 16h ago
Tissue Regeneration Engineering Market Approximate Analysis, Status, Dynamics, Challenges and Development Trends by 2027|Top Countries Data and COVID 19 Impact on Top Key Players
May 11, 2021 (The Expresswire) -- The worldwide “Tissue Regeneration Engineering Market” research report is involved a detailed investigation of the market...
The Express Wire · 1d ago
Stocks That Hit 52-Week Lows On Monday
  Monday morning saw 78 companies set new 52-week lows.
Benzinga · 1d ago
DJ Athersys, Inc. Management on Q1 2021 Results -- Earnings Call Transcript >ATHX
Dow Jones · 2d ago
Tissue Regeneration Market to Register Incremental Revenue Opportunities During the Forecast Period 2021-2027
May 07, 2021 (Heraldkeepers) -- The Global Tissue Regeneration Market is segmented on the lines of its technology, treatment, application and regional. Based...
Heraldkeepers · 4d ago
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 4d ago
Needham Thinks Athersys’ Stock is Going to Recover
In a report released today, Chad Messer from Needham maintained a Buy rating on Athersys (ATHX), with a price target of $5.00. The company's shares closed
SmarterAnalyst · 4d ago
Athersys Q1 EPS $(0.13) Misses $(0.09) Estimate
Athersys (NASDAQ:ATHX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same
Benzinga · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHX. Analyze the recent business situations of Athersys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHX stock price target is 5.25 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 198
Institutional Holdings: 59.70M
% Owned: 27.04%
Shares Outstanding: 222.09M
TypeInstitutionsShares
Increased
46
3.70M
New
14
496.25K
Decreased
38
5.60M
Sold Out
15
522.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Director
Ismail Kola
President/Chief Executive Officer/Chief Operating Officer
William Lehmann
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Senior Vice President - Finance
Laura Campbell
Senior Vice President
Maia Hansen
Director
Hardy Kagimoto
Director
Katherine Kalin
Director
Baiju Shah
Director
Jane Wasman
Independent Director
Lorin Randall
Independent Director
Kenneth Traub
Independent Director
Jack Wyszomierski
No Data
About ATHX
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Webull offers kinds of Athersys Inc stock information, including NASDAQ:ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.